InMode Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011595993
USD
14.34
0.1 (0.7%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About InMode Ltd. stock-summary
stock-summary
InMode Ltd.
Pharmaceuticals & Biotechnology
Inmode Ltd is an Israel-based company. It designs, develops, manufactures and commercializes energy-based, minimally-invasive surgical aesthetic and medical treatment solutions. The Company’s proprietary technologies are used by physicians to remodel subdermal adipose, or fatty, tissue in a variety of procedures including fat reduction with simultaneous skin tightening, face and body contouring and ablative skin rejuvenation treatments. Its products target a wide array of procedures including simultaneous fat killing and skin tightening, permanent hair reduction, skin appearance and texture, among others. The Company’s products may be used on a variety of body parts, including the face, neck, abdomen, upper arms, thighs and intimate feminine regions. It owns six product platforms: BodyTite, Optimas, Votiva, Contoura, Triton and EmbraceRF. All are market and sell traditionally to plastic and facial surgeons, aesthetic surgeons and dermatologists, among others.
Company Coordinates stock-summary
Company Details
Tavor Building, Sha'ar Yokneam, Pob 533 , YOKNEAM None : 2069200
stock-summary
Tel: 972 4 90974701 917 6078654
stock-summary
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 99 Schemes (24.51%)

Foreign Institutions

Held by 150 Foreign Institutions (23.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Moshe Mizrahy
Chairman of the Board, Chief Executive Officer
Dr. Michael Kreindel
Chief Technology Officer, Director
Dr. Michael Anghel
Independent Director
Mr. Bruce Mann
Independent Director
Dr. Hadar Ron
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
96 Million
(Quarterly Results - Jun 2025)
Net Profit:
27 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,338 Million (Small Cap)

stock-summary
P/E

7.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.81

stock-summary
Return on Equity

28.44%

stock-summary
Price to Book

2.13